10.06

0.79% -0.08

After Hours: 10.06

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $10.06, with a volume of 140.63K. It is down -0.79% in the last 24 hours and down -7.88% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$10.14

Open:

$10.36

24h Volume:

140.63K

Relative Volume:

0.48

Market Cap:

$199.11M

Revenue:

$33.18M

Net Income/Loss:

$-85.15M

P/E Ratio:

-3.3473

EPS:

-3.0054

Net Cash Flow:

$-58.25M

1W Performance:

-5.45%

1M Performance:

-7.88%

6M Performance:

-47.60%

1Y Performance:

-30.04%

1-Day Range:

$10.02

$10.36

1-Week Range:

$9.915

$10.97

52-Week Range:

$9.69

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	10.06	199.11M	33.18M	-85.15M	-58.25M	-3.0054
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

04:59 AM

Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head - Stock Titan

Jul 22, 2026

Discipline and Rules-Based Execution in KROS Response - Stock Traders Daily

Jul 22, 2026

Keros Therapeutics CFO Keith Regnante resigns effective Aug. 3 - scanx.trade

Jul 22, 2026

Jul 20, 2026

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com

Jul 20, 2026

Keros Therapeutics (KROS) Holds Steady Near Support LevelUp Down Volume - dars.gov.et

Jul 20, 2026

Jul 17, 2026

Keros Therapeutics (KROS) director adds 1,000 shares under 10b5-1 plan - Stock Titan

Jul 17, 2026

BlackRock Portfolio Management (KROS) discloses 5.7% ownership in Keros Therapeutics - Stock Titan

Jul 17, 2026

Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher - simplywall.st

Jul 17, 2026

Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN

Jul 17, 2026

Jul 16, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Jul 16, 2026

Jul 10, 2026

KROS Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Progress ContinuesEPS Growth Rate - dars.gov.et

Jul 10, 2026

Jul 07, 2026

KROS Q1 2026 Earnings: EPS Miss of 15.98% as Clinical-Stage Biotech Reports Wider-Than-Expected LossProfit Announcement - dars.gov.et

Jul 07, 2026

Keros Therapeutics | DEFA14A: Others - Moomoo

Jul 07, 2026

Jul 06, 2026

Form 4 Keros Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

Keros Therapeutics (KROS) grants director Anne Prener RSUs and stock options - Stock Titan

Jul 06, 2026

Director Anne Prener files Form 3 insider report at Keros Therapeutics (KROS) - Stock Titan

Jul 06, 2026

Jul 02, 2026

Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors - TipRanks

Jul 02, 2026

Jul 01, 2026

KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineProfit Inflection Point - dars.gov.et

Jul 01, 2026

Jun 29, 2026

Behavioral Patterns of KROS and Institutional Flows - Stock Traders Daily

Jun 29, 2026

Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value-Defensive Index - marketscreener.com

Jun 28, 2026

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Defensive Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026